COVID-19: First copies of Gilead virus drug to start selling in Bangladesh | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Saturday
July 12, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
SATURDAY, JULY 12, 2025
First copies of Gilead virus drug to start selling in Bangladesh

Coronavirus chronicle

Arun Devnath
21 May, 2020, 12:20 pm
Last modified: 21 May, 2020, 12:43 pm

Related News

  • MoU inked to promote Dhaka-Bangkok trade
  • 2 cleaners killed in covered van crash in Dhaka
  • One dies from COVID-19 in 24 hrs
  • Ulan Daspara: Remnants of a fishing village in Dhaka
  • Online GD service to be launched in Dhaka, Mymensingh tomorrow

First copies of Gilead virus drug to start selling in Bangladesh

The Dhaka-based Beximco, which counts Norges Bank as one of its investors, will sell remdesivir for about 6,000 taka ($71) a vial to private clinics but will give it free to state-run hospitals treating Covid-19 patients

Arun Devnath
21 May, 2020, 12:20 pm
Last modified: 21 May, 2020, 12:43 pm
A vial of Remdesivir. Photographer: Ulrich Perrey/Getty Images
A vial of Remdesivir. Photographer: Ulrich Perrey/Getty Images

Bangladesh's Beximco Pharmaceuticals Ltd. said it has become the world's first company to start selling the generic version of Gilead Sciences Inc.'s antiviral drug on mounting urgency to treat the infection caused by the deadly coronavirus across the developing world.

The Dhaka-based Beximco, which counts Norges Bank as one of its investors, will sell remdesivir for about 6,000 taka ($71) a vial to private clinics but will give it free to state-run hospitals treating Covid-19 patients, Rabbur Reza, chief operating officer at the company, said in an interview. A critically ill Covid-19 patient will need at least six vials, he said.

Bangladesh can produce generic versions of patented drugs under World Trade Organization provisions that grant least developed countries a waiver from seeking licenses. Remdesivir was cleared by U.S. drug regulator for emergency use in Covid-19 patients, becoming the first medication backed by early clinical data to be made available to fight the novel pathogen.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

'Receiving Queries'

"We're also receiving queries from other countries," Reza said. "The drug will not be supplied through traditional distribution channels. If some governments need our drug, we'll export it."

Bangladesh had more than 26,000 infected cases as of Wednesday, while the disease had killed 386, according to data from Johns Hopkins University

The United Nations-backed Medicines Patent Pool, which is helping Gilead find partners, contacted Beximco asking if it was interested in the voluntary licensing for remdesivir, said Reza. Beximco is waiting to hear back, he said.

A Gilead representative didn't respond to an email seeking comment.

Gilead Gives Royalty-Free Remdesivir Licenses to Five Drugmakers

Gilead has since licensed five companies including Cipla Ltd. and Mylan NV in India and Ferozsons Laboratories Ltd. in Pakistan to make generic versions of the drug and sell in 127 countries.

Norway's Norges Bank, the world's biggest sovereign fund, controls 3% of Beximco, according to data compiled by Bloomberg. Beximco will sell the drug under the brand name bemsivir, according to a statement from the company.


Disclaimer: This article first appeared on Bloomberg.com, and is published by special syndication arrangement."

Top News

COVID-19 / Dhaka / Beximco Pharmaceuticals Ltd / remdesivir

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Representational image
    In addition to 35% tariff, US demands 40% local value addition for 'Made in Bangladesh' goods
  • Bangladesh and US hold tariff talks on 11 July 2025. Photo: CA Press Wing
    Dhaka, Washington to continue inter-ministerial dialogue as tariff talks end without full consensus
  • After indias visa restriction, China's Kunming is drawing bangladeshi patients
    After indias visa restriction, China's Kunming is drawing bangladeshi patients

MOST VIEWED

  • In terms of stream of education, girls maintained their excellence as well. Photo: TBS
    SSC 2025: Girls dominate boys by over 5%
  • Photo: Mohammad Minhaj Uddin/TBS
    SSC, equivalent results: Pass rate drops to 68.45%, GPA-5 also declines
  • The overall pass rate across all boards this year, 68.45%, is significantly lower than last year's. Photo: Focus Bangla
    SSC 2025: Rajshahi board records highest pass rate, Barishal lowest
  • How S Alam’s Global Islami Bank cooked Tk2,259cr loss into Tk128cr profit
    How S Alam’s Global Islami Bank cooked Tk2,259cr loss into Tk128cr profit
  • Representational image. Photo: TBS
    SSC 2025: 73.63% pass rate among technical students, 68.09% at Madrasahs
  • Economist Abul Barkat; Photo: Courtesy
    Economist Abul Barkat arrested in graft case

Related News

  • MoU inked to promote Dhaka-Bangkok trade
  • 2 cleaners killed in covered van crash in Dhaka
  • One dies from COVID-19 in 24 hrs
  • Ulan Daspara: Remnants of a fishing village in Dhaka
  • Online GD service to be launched in Dhaka, Mymensingh tomorrow

Features

After indias visa restriction, China's Kunming is drawing bangladeshi patients

After indias visa restriction, China's Kunming is drawing bangladeshi patients

12h | Panorama
Photo: Collected/BBC

What Hitler’s tariff policy misfire can teach the modern world

1d | The Big Picture
Illustration: TBS

Behind closed doors: Why women in Bangladesh stay in abusive marriages

1d | Panorama
Purbachl’s 144-acre Sal forest is an essential part of the area’s biodiversity. Within it, 128 species of plants and 74 species of animals — many of them endangered — have been identified. Photo: Syed Zakir Hossain/TBS

A forest saved: Inside the restoration of Purbachal's last Sal grove

1d | Panorama

More Videos from TBS

Renowned economist Abul Barkat imprisoned

Renowned economist Abul Barkat imprisoned

11h | TBS Today
All of Iran's uranium still intact, Israel claims

All of Iran's uranium still intact, Israel claims

10h | TBS World
Trump-Netanyahu in new strategy on Gaza issue

Trump-Netanyahu in new strategy on Gaza issue

12h | TBS World
Shocking science: why birds stay safe on electricity lines

Shocking science: why birds stay safe on electricity lines

13h | TBS Stories
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net